LU84632A1 - Stabilisierte insulinloesungen und verfahren zu ihrer herstellung - Google Patents
Stabilisierte insulinloesungen und verfahren zu ihrer herstellung Download PDFInfo
- Publication number
- LU84632A1 LU84632A1 LU84632A LU84632A LU84632A1 LU 84632 A1 LU84632 A1 LU 84632A1 LU 84632 A LU84632 A LU 84632A LU 84632 A LU84632 A LU 84632A LU 84632 A1 LU84632 A1 LU 84632A1
- Authority
- LU
- Luxembourg
- Prior art keywords
- insulin
- zinc
- solution according
- solution
- hexamer
- Prior art date
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 316
- 229940125396 insulin Drugs 0.000 claims description 154
- 108090001061 Insulin Proteins 0.000 claims description 148
- 102000004877 Insulin Human genes 0.000 claims description 148
- 239000011701 zinc Substances 0.000 claims description 107
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 65
- 229910052725 zinc Inorganic materials 0.000 claims description 65
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 claims description 37
- 239000008139 complexing agent Substances 0.000 claims description 28
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 27
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 20
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 19
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 15
- ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical group [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- 239000004246 zinc acetate Substances 0.000 claims description 12
- 239000004471 Glycine Substances 0.000 claims description 10
- 235000011187 glycerol Nutrition 0.000 claims description 10
- 239000003755 preservative agent Substances 0.000 claims description 10
- 150000003751 zinc Chemical class 0.000 claims description 10
- 230000002335 preservative effect Effects 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 239000006179 pH buffering agent Substances 0.000 claims description 5
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 claims description 4
- 101710186643 Insulin-2 Proteins 0.000 claims description 3
- 239000000872 buffer Substances 0.000 claims description 2
- 239000007951 isotonicity adjuster Substances 0.000 claims description 2
- 239000011592 zinc chloride Substances 0.000 claims description 2
- 235000005074 zinc chloride Nutrition 0.000 claims description 2
- 229920001202 Inulin Polymers 0.000 claims 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims 1
- 229940029339 inulin Drugs 0.000 claims 1
- 239000000243 solution Substances 0.000 description 83
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 28
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 238000002360 preparation method Methods 0.000 description 13
- 238000001914 filtration Methods 0.000 description 11
- 239000007864 aqueous solution Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 7
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 6
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 6
- 108010005991 Pork Regular Insulin Proteins 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 108010066090 neutral insulin Proteins 0.000 description 5
- 101000993800 Sus scrofa Insulin Proteins 0.000 description 4
- 238000013112 stability test Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 206010061592 cardiac fibrillation Diseases 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 230000002600 fibrillogenic effect Effects 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 238000005086 pumping Methods 0.000 description 3
- 230000000087 stabilizing effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 description 2
- 101001011741 Bos taurus Insulin Proteins 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- IXIBAKNTJSCKJM-BUBXBXGNSA-N bovine insulin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 IXIBAKNTJSCKJM-BUBXBXGNSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- QNDQILQPPKQROV-UHFFFAOYSA-N dizinc Chemical compound [Zn]=[Zn] QNDQILQPPKQROV-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 235000014304 histidine Nutrition 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229940119528 pork insulin Drugs 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- KZEVSDGEBAJOTK-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[5-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CC=1OC(=NN=1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O KZEVSDGEBAJOTK-UHFFFAOYSA-N 0.000 description 1
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 1
- JQMFQLVAJGZSQS-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)NC1=CC2=C(NC(O2)=O)C=C1 JQMFQLVAJGZSQS-UHFFFAOYSA-N 0.000 description 1
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010008488 Glycylglycine Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 229930003836 cresol Natural products 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- NBZBKCUXIYYUSX-UHFFFAOYSA-N iminodiacetic acid Chemical compound OC(=O)CNCC(O)=O NBZBKCUXIYYUSX-UHFFFAOYSA-N 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
Classifications
-
- H—ELECTRICITY
- H05—ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR
- H05K—PRINTED CIRCUITS; CASINGS OR CONSTRUCTIONAL DETAILS OF ELECTRIC APPARATUS; MANUFACTURE OF ASSEMBLAGES OF ELECTRICAL COMPONENTS
- H05K13/00—Apparatus or processes specially adapted for manufacturing or adjusting assemblages of electric components
- H05K13/06—Wiring by machine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Endocrinology (AREA)
- Microelectronics & Electronic Packaging (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical & Material Sciences (AREA)
- Manufacturing & Machinery (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK49182 | 1982-02-05 | ||
| DK49182 | 1982-02-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LU84632A1 true LU84632A1 (fr) | 1983-09-08 |
Family
ID=8094159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LU84632A LU84632A1 (fr) | 1982-02-05 | 1983-02-04 | Stabilisierte insulinloesungen und verfahren zu ihrer herstellung |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US4476118A (it) |
| JP (1) | JPS58192818A (it) |
| AT (1) | AT382780B (it) |
| AU (1) | AU549981B2 (it) |
| BE (1) | BE895832A (it) |
| CA (1) | CA1203476A (it) |
| CH (1) | CH657530A5 (it) |
| DE (1) | DE3303860A1 (it) |
| ES (1) | ES519533A0 (it) |
| FI (1) | FI78616C (it) |
| FR (1) | FR2521009B1 (it) |
| GB (1) | GB2114573B (it) |
| GR (1) | GR77388B (it) |
| IE (1) | IE54548B1 (it) |
| IT (1) | IT1178455B (it) |
| LU (1) | LU84632A1 (it) |
| NL (1) | NL187269C (it) |
| NO (1) | NO161204C (it) |
| NZ (1) | NZ203189A (it) |
| PT (1) | PT76195B (it) |
| SE (1) | SE460948B (it) |
| ZA (1) | ZA83742B (it) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE50502T1 (de) * | 1984-06-09 | 1990-03-15 | Hoechst Ag | Insulinzubereitungen, verfahren zu deren herstellung und deren verwendung. |
| JP2520262B2 (ja) * | 1987-08-21 | 1996-07-31 | 春幸 川原 | パツチテスト材料 |
| US4789660A (en) * | 1987-09-10 | 1988-12-06 | American Home Products Corporation | Insulin administration using methyl and propyl paraben |
| US5130298A (en) * | 1989-05-16 | 1992-07-14 | Ethicon, Inc. | Stabilized compositions containing epidermal growth factor |
| US5534488A (en) * | 1993-08-13 | 1996-07-09 | Eli Lilly And Company | Insulin formulation |
| US5474978A (en) * | 1994-06-16 | 1995-12-12 | Eli Lilly And Company | Insulin analog formulations |
| YU18596A (sh) * | 1995-03-31 | 1998-07-10 | Eli Lilly And Company | Analogne formulacije monomernog insulina |
| CA2236579C (en) * | 1995-11-13 | 2009-06-30 | Minimed, Inc. | Methods and compositions for the delivery of monomeric proteins |
| EP0891419A4 (en) * | 1996-03-12 | 2000-03-01 | Life Technologies Inc | NUTRIENT ADDITIVE FOR HEMATOPOETIC CELL CULTURES |
| DK0821006T3 (da) * | 1996-07-26 | 2004-08-16 | Aventis Pharma Gmbh | Insulinderivater med öget zinkbinding |
| PE79099A1 (es) * | 1997-06-13 | 1999-08-24 | Lilly Co Eli | Formulaciones de insulina estables |
| DK1283051T3 (da) * | 1997-06-13 | 2006-10-16 | Lilly Co Eli | Stabile insulinformuleringer |
| WO1999024071A1 (en) * | 1997-11-12 | 1999-05-20 | Alza Corporation | Method for decreasing self-association of polypeptides |
| DE19825447A1 (de) | 1998-06-06 | 1999-12-09 | Hoechst Marion Roussel De Gmbh | Neue Insulinanaloga mit erhöhter Zinkbildung |
| ATE277630T1 (de) * | 1998-10-16 | 2004-10-15 | Novo Nordisk As | Stabile konzentrierte insulin präparationen zur pulmonaren verabreichung |
| DE19930676B4 (de) * | 1999-07-02 | 2006-01-19 | Sanofi-Aventis Deutschland Gmbh | Verfahren zur Stabilisierung von Insulin, Insulinderivaten und/oder deren Vorläufer in komplexen Mischungen bei deren Lagerung in wäßrigen Lösungsmitteln |
| WO2001072323A2 (en) * | 2000-03-24 | 2001-10-04 | Genentech, Inc. | Use of insulin for the treatment of cartilagenous disorders |
| JP4147234B2 (ja) * | 2004-09-27 | 2008-09-10 | キヤノン株式会社 | 吐出用液体、吐出方法、カートリッジ及び吐出装置 |
| JP5599543B2 (ja) | 2002-05-07 | 2014-10-01 | ノヴォ ノルディスク アー／エス | 単量体インスリン及びアシル化インスリンを含む可溶性製剤 |
| US20050065066A1 (en) * | 2002-12-20 | 2005-03-24 | Kaarsholm Niels Christian | Stabilised insulin compositions |
| EP1585541B1 (en) * | 2002-12-20 | 2007-11-14 | Novo Nordisk A/S | Pharmaceutical compositions comprising insulin and legends of insulin hexamer |
| WO2004096266A1 (en) * | 2003-05-02 | 2004-11-11 | Novo Nordisk A/S | Improved physical stability of insulin formulations |
| EP2264065B1 (en) * | 2003-08-05 | 2017-03-08 | Novo Nordisk A/S | Novel insulin derivatives |
| UA103758C2 (ru) | 2004-07-19 | 2013-11-25 | Биокон Лимитед | Конъюгаты олигомеров инсулина, их композиции и применение |
| PT1969004E (pt) | 2005-12-28 | 2011-11-25 | Novo Nordisk As | Composições que compreendem uma insulina acilada e zinco e método para criar tais composições |
| US20090136538A1 (en) * | 2006-05-22 | 2009-05-28 | Jan Jezek | Stable vaccine formulation |
| GB0700523D0 (en) * | 2007-01-11 | 2007-02-21 | Insense Ltd | The Stabilisation Of Proteins |
| EP2134351B1 (en) | 2007-03-13 | 2016-04-27 | Nutrition 21, Inc. | Methods and compositions for the sustained release of chromium |
| ES2744384T3 (es) * | 2007-06-13 | 2020-02-24 | Novo Nordisk As | Formulación farmacéutica que comprende un derivado de insulina |
| WO2009002867A2 (en) | 2007-06-26 | 2008-12-31 | Nutrition 21, Inc. | Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement |
| PL2209800T3 (pl) * | 2007-11-16 | 2013-12-31 | Novo Nordisk As | Stabilne kompozycje farmaceutyczne zawierające liraglutyd i degludec |
| EP2328607A1 (en) * | 2008-07-16 | 2011-06-08 | Arecor Limited | Stable formulation of a therapeutic protein |
| EP2341940A1 (en) * | 2008-07-16 | 2011-07-13 | Arecor Limited | The stabilisation of proteins |
| US9603904B2 (en) * | 2008-10-30 | 2017-03-28 | Novo Nordisk A/S | Treating diabetes melitus using insulin injections with less than daily injection frequency |
| US9060927B2 (en) | 2009-03-03 | 2015-06-23 | Biodel Inc. | Insulin formulations for rapid uptake |
| BR112013010345A2 (pt) | 2010-10-27 | 2017-07-25 | Novo Nordisk As | tratamento de diabetes melitus usando as injeções de insulina administradas com intervalos de variação da injeção |
| WO2012119007A1 (en) | 2011-03-01 | 2012-09-07 | N21 Acquisition Holding, Llc | Compositions of insulin and chromium for the treatment and prevention of diabetes, hypoglycemia and related disorders |
| WO2014096985A2 (en) | 2012-12-19 | 2014-06-26 | Wockhardt Limited | A stable aqueous composition comprising human insulin or an analogue or derivative thereof |
| PL2919804T3 (pl) | 2012-11-13 | 2018-07-31 | Adocia | Szybko działająca formulacja insuliny zawierająca podstawiony związek anionowy |
| RU2015130613A (ru) | 2012-12-26 | 2017-01-31 | Вокхардт Лимитед | Фармацевтическая композиция |
| TWI641381B (zh) * | 2013-02-04 | 2018-11-21 | 法商賽諾菲公司 | 胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物 |
| EP2991672A1 (en) | 2013-04-30 | 2016-03-09 | Novo Nordisk A/S | Novel administration regime |
| WO2015084694A2 (en) * | 2013-12-04 | 2015-06-11 | Merck Sharp & Dohme Corp. | Method for preparing crystalline insulin |
| AR102869A1 (es) | 2014-12-16 | 2017-03-29 | Lilly Co Eli | Composiciones de insulina de rápida acción |
| JO3749B1 (ar) | 2015-08-27 | 2021-01-31 | Lilly Co Eli | تركيبات إنسولين سريعة المفعول |
| CN109069532A (zh) | 2016-02-11 | 2018-12-21 | 营养21有限责任公司 | 含铬组合物用于改善健康和健身 |
| CA3034971A1 (en) * | 2016-09-29 | 2018-04-05 | Arecor Limited | A pharmaceutical insulin formulation |
| JP6920471B2 (ja) | 2017-06-01 | 2021-08-18 | イーライ リリー アンド カンパニー | 迅速に作用するインスリン組成物 |
| US10335464B1 (en) | 2018-06-26 | 2019-07-02 | Novo Nordisk A/S | Device for titrating basal insulin |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2882202A (en) * | 1950-04-05 | 1959-04-14 | Novo Terapeutisk Labor As | Insulin crystal preparations and methods of producing them |
| US2787575A (en) * | 1950-11-22 | 1957-04-02 | Organon | Zinc-glycine-insulin composition and production thereof |
| US2882203A (en) * | 1951-06-26 | 1959-04-14 | Novo Terapeutisk Labor As | Injectable insulin preparation with protracted effect |
| DE1044360B (de) * | 1953-08-19 | 1958-11-20 | Roskilde Medical Company Ltd R | Verfahren zur Herstellung von Zinkinsulin mit erhoehtem Zinkgehalt |
| DE956098C (de) * | 1954-02-18 | 1957-01-10 | Dr Dr Guenther Weitzel | Verfahren zur Herstellung zinkreicher Insulin-Komplexverbindungen |
| US3058885A (en) * | 1957-06-08 | 1962-10-16 | Novo Terapeutisk Labor As | Process for treatment of insulin crystals and for production of insulin preparationstherefrom |
| US3014842A (en) * | 1957-08-10 | 1961-12-26 | Novo Terapeutish Lab A S | Injectable bovine insulin crystal suspensions and process of producing same |
| US3091573A (en) * | 1958-05-12 | 1963-05-28 | Novo Terapeutisk Labor As | Quick acting insulin preparation |
| FR1263220A (fr) * | 1958-08-01 | 1961-06-09 | Novo Terapeutisk Labor As | Procédé de production d'une préparation d'insuline à action rapide |
| DK116527B (da) * | 1967-03-01 | 1970-01-19 | Nordisk Insulinlab | Fremgangsmåde til fremstilling af en hurtigtvirkende, holdbar, neutral opløsning af rent krystallinsk okseinsulin eller okseinsulin, der ved tilsætning af Zn er krystalliserbart i vand, eller blandinger af okseinsulin og insulin af anden oprindelse. |
| GB1285023A (en) * | 1968-08-09 | 1972-08-09 | Novo Terapeutisk Labor As | Improvements in or relating to injectable insulin preparations |
| US3657425A (en) * | 1969-03-12 | 1972-04-18 | Burroughs Wellcome Co | Beef insulin preparations |
| DE3064888D1 (en) * | 1979-04-30 | 1983-10-27 | Hoechst Ag | Aqueous solutions of proteins stable against denaturization, process for their manufacture, and their utilization |
| DK80781A (da) * | 1980-02-29 | 1981-08-30 | Hospital For Sick Children | Oploesninger af polypeptider |
| EP0102976A1 (en) * | 1982-03-03 | 1984-03-21 | Nordisk Insulinlaboratorium | A process for producing an insulin preparation |
-
1983
- 1983-02-03 FI FI830375A patent/FI78616C/fi not_active IP Right Cessation
- 1983-02-04 BE BE6/47775A patent/BE895832A/fr not_active IP Right Cessation
- 1983-02-04 IE IE220/83A patent/IE54548B1/en not_active IP Right Cessation
- 1983-02-04 SE SE8300598A patent/SE460948B/sv not_active IP Right Cessation
- 1983-02-04 AT AT0038983A patent/AT382780B/de not_active IP Right Cessation
- 1983-02-04 ES ES519533A patent/ES519533A0/es active Granted
- 1983-02-04 DE DE19833303860 patent/DE3303860A1/de active Granted
- 1983-02-04 JP JP58016303A patent/JPS58192818A/ja active Granted
- 1983-02-04 NL NLAANVRAGE8300440,A patent/NL187269C/xx not_active IP Right Cessation
- 1983-02-04 GR GR70416A patent/GR77388B/el unknown
- 1983-02-04 LU LU84632A patent/LU84632A1/de unknown
- 1983-02-04 US US06/463,730 patent/US4476118A/en not_active Expired - Lifetime
- 1983-02-04 PT PT76195A patent/PT76195B/pt unknown
- 1983-02-04 AU AU11136/83A patent/AU549981B2/en not_active Expired
- 1983-02-04 FR FR8301790A patent/FR2521009B1/fr not_active Expired
- 1983-02-04 IT IT19420/83A patent/IT1178455B/it active
- 1983-02-04 NO NO830385A patent/NO161204C/no not_active IP Right Cessation
- 1983-02-04 CH CH657/83A patent/CH657530A5/de not_active IP Right Cessation
- 1983-02-04 ZA ZA83742A patent/ZA83742B/xx unknown
- 1983-02-04 NZ NZ203189A patent/NZ203189A/en unknown
- 1983-02-04 GB GB08303133A patent/GB2114573B/en not_active Expired
- 1983-02-04 CA CA000420907A patent/CA1203476A/en not_active Expired
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3303860C2 (it) | ||
| AT408611B (de) | Insulinanalogon-protamin-komplex | |
| AT408720B (de) | Parenterale pharmazeutische formulierung eines humaninsulinanalogon-komplexes | |
| EP0357978B1 (de) | Pharmazeutische Zubereitung zur Behandlung des Diabetes mellitus | |
| DE69428860T2 (de) | Insulin Formulierung | |
| DE69708121T2 (de) | Halogenid-enthaltende insulinzubereitungen | |
| DE69834956T2 (de) | Stabile Insulinformulierungen | |
| DE3240177C2 (it) | ||
| DE69434963T2 (de) | Selektiv auf die leber wirkende pharmazeutisch aktive substanz | |
| DE69737995T2 (de) | INSULINPREPARATION MIT MAnnitol | |
| DE68905203T2 (de) | Verwendung von igf i zur herstellung eines praeparates fuer die behandlung von nierenkrankheiten. | |
| DE10114178A1 (de) | Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität | |
| DE69115590T2 (de) | 4-Chinolonderivate mit einem zweiwertigen Metallion komplexiert enthaltende Zusammensetzung | |
| DE3837825A1 (de) | Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung | |
| WO2011003822A2 (de) | Insulinzubereitungen enthaltend methionin | |
| DE69827357T2 (de) | Menschliches Wachstumshormon enthaltende pharmazeutische Zusammensetzung | |
| WO2011003823A1 (de) | Langsamwirkende insulinzubereitungen | |
| CH652031A5 (de) | Stabilisierte insulinpraeparate und verfahren zu deren herstellung. | |
| EP0291863B1 (de) | Mischkristalle aus Insulin und Insulinderivaten, Verfahren zur Herstellung dieser Mischkristalle und diese Mischkristalle enthaltende pharmazeutische Mittel | |
| EP0166971B1 (de) | Insulinzubereitungen, Verfahren zu deren Herstellung und deren Verwendung | |
| DE1212679B (de) | Verfahren zur Herstellung von Insulinloesungen | |
| EP0187361A2 (de) | Präparate mit verzögerter Wirkung, Verfahren zu deren Herstellung sowie entprechende Mittel zur Human- bzw. veterinärmedizinischen Anwendung | |
| DE60001489T2 (de) | Pharmazeutische zubereitung für die intravenöse oder intramuskuläre verabreichung von octreotid | |
| AT401469B (de) | Pharmazeutische wässrige lösung zur parenteralen anwendung enthaltend einen in situ gebildeten komplex von einem alkaloid mit bis-indol-gerüst, sowie verfahren zu deren herstellung | |
| DE2427732A1 (de) | Mittel zum anaesthesieren von saeugetieren |